Salary: Grade 7: £32,236 - £39,609 p.a.
We are seeking to recruit a suitably experienced person with strong organisational skills to manage the Haematopoietic Stem Cell Biology (HSCB) laboratory. You will play a key role in maintaining the laboratory, and will also participate in research projects, working closely with scientists, postdocs and PhD students in the laboratory. You will oversee clinical studies for the collection and processing of patient samples in the laboratory through the INForMeD study (a sample collection study run by Professor Mead), this will provide an opportunity to learn new, or develop existing skills in clinical study management.
The HSCB laboratory is based within the excellent research environment of the Weatherall Institute of Molecular Medicine. Members of the laboratory are focusing on understanding the molecular regulation of normal blood formation and the blood forming stem cells in particular, and how these processes are dysregulated in leukaemia.
You will hold a degree in a biomedical, cell biology, immunology, haematology or associated subject. You will have knowledge and experience of the management and operation of containment level 2 laboratories and Good Laboratory Practice. Previous experience of laboratory management, COSHH regulations, cell/tissue culture and molecular biology are essential. You will have good organizational and time management skills with experience of implementing Health and Safety procedures and responding to the diverse needs of research groups with competing pressures.
The position is available immediately and is fixed-term until 31 March 2020 in the first instance, with the potential for follow-on funding.
Informal enquiries should be directed to Professor Adam Mead (email@example.com).
Candidates are encouraged to discuss their needs and preferences for work arrangements at interview. Applications for this vacancy are to be made online.
The closing date for applications is 12.00 noon on 8 April 2019. Interviews will take place week beginning 22 April 2019.